Literature DB >> 23912183

Tetramethylpyrazine inhibits osteosarcoma cell proliferation via downregulation of NF-κB in vitro and in vivo.

Yong Wang1, Qin Fu, Wei Zhao.   

Abstract

Tetramethylpyrazine (TMP) is an effective component of the traditional Chinese medicine Chuanxiong, which has been reported to have beneficial effects in various types of cancer. However, the activity and mechanism of action of TMP in osteosarcoma (OS) have not been elucidated to date. The aim of the present study was to investigate the inhibitory effect of TMP on OS and its underlying mechanism of action. OS cells were treated with various concentrations of TMP for 48 h. BALB/c nude mice with OS were treated with an intraperitoneal injection of TMP at a dose of 100 mg/kg every other day for 28 days. Cell proliferation was evaluated using an MTT assay. Cell cycle and apoptosis were measured using flow cytometry. The protein expression of nuclear and cytosolic nuclear factor‑κB (NF-κB) p65, BCL‑2 and cyclin D1 was measured using western blot analysis. TMP inhibited the proliferation of OS cells (MG-63, SAOS-2 and U2OS) in a dose‑dependent manner. Additionally, TMP significantly induced apoptosis and G0/G1 arrest in MG-63 OS cells (P<0.05). TMP upregulated the protein expression of cytosolic NF-κB p65, while downregulating the protein expression of nuclear NF-κB p65, BCL-2 and cyclin D1. Furthermore, TMP exerted a significant antitumor effect against OS in a xenograft tumor mouse model and exhibited a low toxicity. The present study provided fundamental evidence for the application of TMP in chemotherapy against OS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912183     DOI: 10.3892/mmr.2013.1611

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  10 in total

1.  Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3.

Authors:  Jianliang Shen; Linwen Zeng; Liangming Pan; Shaofeng Yuan; Ming Wu; Xiongdong Kong
Journal:  Oncol Lett       Date:  2018-01-24       Impact factor: 2.967

2.  Reversal of doxorubicin-resistance by Salvia miltiorrhiza ligustrazine in the SHG44/doxorubicin glioma drug-resistant cell line.

Authors:  Feng Wang; Ning Huang; Qiang Yang; Jun Liu; Jin Chen
Journal:  Oncol Lett       Date:  2017-08-18       Impact factor: 2.967

3.  Tetramethylpyrazine (TMP) protects rats against acute pancreatitis through NF-κB pathway.

Authors:  Longying Chen; Yongjun Chen; Hao Yun; Zhang Jianli
Journal:  Bioengineered       Date:  2019-12       Impact factor: 3.269

Review 4.  Tetramethylpyrazine: A Review of Its Antitumor Potential and Mechanisms.

Authors:  Shaojie Yang; Shuodong Wu; Wanlin Dai; Liwei Pang; Yaofeng Xie; Tengqi Ren; Xiaolin Zhang; Shiyuan Bi; Yuting Zheng; Jingnan Wang; Yang Sun; Zhuyuan Zheng; Jing Kong
Journal:  Front Pharmacol       Date:  2021-12-16       Impact factor: 5.810

5.  Down-regulation of MRPS23 inhibits LPS-induced proliferation and invasion via regulation of the NF-κB signaling pathway in osteosarcoma cells.

Authors:  Ai-Guo Liu; Ke-Lin Xu; Wei-Lin Wang; Bing-Kang Zhou; Qing-Gong Guo
Journal:  RSC Adv       Date:  2019-04-04       Impact factor: 4.036

6.  Tetramethylpyrazine inhibits proliferation of colon cancer cells in vitro.

Authors:  Hua Li; Yan-Xu Hou; Yu Yang; Qing-Qiang He; Tian-Hua Gao; Xiao-Feng Zhao; Zhi-Bin Huo; Shu-Bo Chen; Deng-Xiang Liu
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

7.  Tectorigenin inhibits osteosarcoma cell migration through downregulation of matrix metalloproteinases in vitro.

Authors:  Yu Guo; Ya-Hong Chen; Zhi-Hua Cheng; Huo-Niu Ou-Yang; Cong Luo; Zhi-Lin Guo
Journal:  Anticancer Drugs       Date:  2016-07       Impact factor: 2.248

Review 8.  Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective.

Authors:  Yingke Zhao; Yue Liu; Keji Chen
Journal:  Oxid Med Cell Longev       Date:  2016-09-07       Impact factor: 6.543

9.  Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.

Authors:  Yi Zhou; Zhigang Ji; Weigang Yan; Zhien Zhou; Hanzhong Li; Yu Xiao
Journal:  Oncol Rep       Date:  2017-06-29       Impact factor: 3.906

10.  Enrichment of Wee1/CDC2 and NF-κB Signaling Pathway Constituents Mutually Contributes to CDDP Resistance in Human Osteosarcoma.

Authors:  Zhengbo Hu; Lugen Li; Wenxing Lan; Xiao Wei; Xiangyuan Wen; Penghuan Wu; Xianliao Zhang; Xinhua Xi; Yufa Li; Liqi Wu; Wenhu Li; Xiaohong Liao
Journal:  Cancer Res Treat       Date:  2021-05-11       Impact factor: 4.679

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.